trending Market Intelligence /marketintelligence/en/news-insights/trending/HLJq3MpSDMB7SjXAZ9PPRA2 content esgSubNav
In This List

US FDA flags violations at Shilpa Medicare's facilities in India

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


US FDA flags violations at Shilpa Medicare's facilities in India

The U.S. Food and Drug Administration informed Shilpa Medicare Ltd. of 10 violations at its special economic zone formulation facilities situated in Telangana, India.

Of the 10 so-called 483 observations, seven are related to procedures and practices while the remaining three are related to the setting of analytical specifications, test procedures and method validation.

The FDA had also found shortcomings in the company's Raichur facility in inspections conducted in December 2016.